Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Arthur Website

Diane C. Arthur, M.D.

Selected Publications

1)  Arthur DC, Bloomfield CD, Lindquist LL, Nesbit ME.
Translocation 4; 11 in acute lymphoblastic leukemia: clinical characteristics and prognostic significance.
Blood. 59: 96-9, 1982.
2)  Arthur DC, Bloomfield CD.
Partial deletion of the long arm of chromosome 16 and bone marrow eosinophilia in acute nonlymphocytic leukemia: a new association.
Blood. 61: 994-8, 1983.
3)  Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA, Arthur DC, Mayer RJ.
Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Cancer Res. 58: 4173-9, 1998.
4)  Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, Zhao H, Ibbotson RE, Orchard JA, Davis Z, Stetler-Stevenson M, Raffeld M, Arthur DC, Marti GE, Wilson WH, Hamblin TJ, Oscier DG, Staudt LM.
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.
Blood. 101: 4944-51, 2003.
5)  Spinner MA, Sanchez LA, Hsu AP, Shaw PA, Zerbe CS, Calvo KR, Arthur DC, Gu W, Gould CM, Brewer CC, Cowen EW, Freeman AF, Olivier KN, Uzel G, Zelazny AM, Daub JR, Spalding CD, Claypool RJ, Giri NK, Alter BP, Mace EM, Orange JS, Cuellar-Rodriguez J, Hickstein DD, Holland SM.
GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity.
Blood. 123: 809-21, 2014.
6)  Shaffer BC, Modric M, Stetler-Stevenson M, Arthur DC, Steinberg SM, Liewehr DJ, Fowler DH, Gale RP, Bishop MR, Pavletic SZ.
Rapid complete donor lymphoid chimerism and graft-versus-leukemia effect are important in early control of chronic lymphocytic leukemia.
Exp. Hematol. 41: 772-8, 2013.
7)  Stetler-Stevenson M, DiGiuseppe J, Arthur D.
Kottke-Marchant K, Davis B, eds.
Myelodysplastic Disorders. In: Laboratory Hematology Practice.
West Sussex: Wiley-Blackwell; 2012. p. 331-344 [Book Chapter]
8)  Degheidy HA, Gadalla SM, Farooqui MZ, Abbasi F, Arthur DC, Bauer SR, Wilson WH, Wiestner A, Stetler-Stevenson MA, Marti GE.
Bcl-2 level as a biomarker for 13q14 deletion in CLL.
Cytometry B Clin Cytom. 84: 237-47, 2012.
9)  Degheidy HA, Venzon DJ, Farooqui MZ, Abbasi F, Arthur DC, Wilson WH, Wiestner A, Stetler-Stevenson MA, Marti GE.
Combined normal donor and CLL: Single tube ZAP-70 analysis.
Cytometry B Clin Cytom. 82: 67-77, 2012.
10)  Shah NN, Bacher U, Fry T, Calvo KR, Stetler-Stevenson M, Arthur DC, Kurlander R, Baird K, Wise B, Giralt S, Bishop M, Hardy NM, Wayne AS.
Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: Diagnostic and therapeutic challenges.
Am. J. Hematol. 87: 916-22, 2012.
Click Here to View Expanded Bibliography.

This page was last updated on 7/11/2014.